Xcovery Revenue and Competitors
Estimated Revenue & Valuation
- Xcovery's estimated annual revenue is currently $3.1M per year.
- Xcovery's estimated revenue per employee is $155,000
Employee Data
- Xcovery has 20 Employees.
- Xcovery grew their employee count by 11% last year.
Xcovery's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CSO | Reveal Email/Phone |
2 | CEO and CMO | Reveal Email/Phone |
3 | VP, Oncology, Late Stage | Reveal Email/Phone |
4 | VP Operations | Reveal Email/Phone |
5 | Chief Financial Officer | Reveal Email/Phone |
6 | Clinical Trial Document Manager | Reveal Email/Phone |
7 | Acting CMO | Reveal Email/Phone |
8 | Quality Assurance Lead-cGMP | Reveal Email/Phone |
9 | Senior QA Document Control Specialist | Reveal Email/Phone |
10 | Jr. Clinical Scientist | Reveal Email/Phone |
Xcovery Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $15.3M | 99 | 5% | N/A | N/A |
#2 | $1.1M | 7 | -30% | N/A | N/A |
#3 | $3.7M | 24 | 4% | N/A | N/A |
#4 | $4.3M | 28 | -3% | N/A | N/A |
#5 | $2.5M | 16 | N/A | N/A | N/A |
#6 | $0.8M | 5 | 0% | N/A | N/A |
#7 | $1.1M | 7 | 0% | N/A | N/A |
#8 | $2.5M | 16 | 7% | N/A | N/A |
#9 | $1.4M | 9 | -25% | N/A | N/A |
#10 | $0.6M | 4 | 0% | N/A | N/A |
What Is Xcovery?
Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases. Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com
keywords:N/A
N/A
Total Funding
20
Number of Employees
$3.1M
Revenue (est)
11%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Xcovery News
Ensartinib is a next generation ALK inhibitor jointly developed by Xcovery and Betta Pharmaceuticals. NMPA's nod in China marked the first...
Ensartinib was previously approved in China as a second-line treatment for ALK-positive NSCLC patients. The drug was codeveloped by Xcovery,...
Other Companies in Palm Beach Gardens
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.2M | 22 | -12% | N/A |
#2 | $2.4M | 23 | -8% | N/A |
#3 | $6.4M | 23 | 5% | N/A |
#4 | $2.3M | 23 | 15% | N/A |
#5 | N/A | 24 | 4% | N/A |